BioCentury
ARTICLE | Clinical News

ABBV-974: Phase II started

February 29, 2016 8:00 AM UTC

Galapagos began the open-label, international Phase II SAPHIRA 2 trial to evaluate 2 doses of twice-daily oral GLPG1837 for 4 weeks in >=6 patients with the S1251N mutation. The company said it expect...